{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T22:22:57Z","timestamp":1790634177869,"version":"4.1.0"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2010,10,19]],"date-time":"2010-10-19T00:00:00Z","timestamp":1287446400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2011,8]]},"DOI":"10.1007\/s00280-010-1479-6","type":"journal-article","created":{"date-parts":[[2010,10,18]],"date-time":"2010-10-18T14:28:24Z","timestamp":1287412104000},"page":"285-291","source":"Crossref","is-referenced-by-count":19,"title":["Nilotinib in patients with GIST who failed imatinib and sunitinib: importance of prior surgery on drug bioavailability"],"prefix":"10.1007","volume":"68","author":[{"given":"Kyu-pyo","family":"Kim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min-Hee","family":"Ryu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Changhoon","family":"Yoo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baek-Yeol","family":"Ryoo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dae Ro","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heung Moon","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jae-Lyun","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mo Youl","family":"Beck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tae Won","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoon-Koo","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2010,10,19]]},"reference":[{"key":"1479_CR1","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1200\/JCO.2007.13.4452","volume":"26","author":"CD Blanke","year":"2008","unstructured":"Blanke CD, Rankin C, Demetri GD et al (2008) Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033. J Clin Oncol 26:626\u2013632","journal-title":"J Clin Oncol"},{"key":"1479_CR2","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1056\/NEJMoa020461","volume":"347","author":"GD Demetri","year":"2002","unstructured":"Demetri GD, von Mehren M, Blanke CD et al (2002) Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 347:472\u2013480","journal-title":"N Engl J Med"},{"key":"1479_CR3","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1016\/S0140-6736(04)17098-0","volume":"364","author":"J Verweij","year":"2004","unstructured":"Verweij J, Casali PG, Zalcberg J et al (2004) Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial. Lancet 364:1127\u20131134","journal-title":"Lancet"},{"issue":"Suppl 2","key":"1479_CR4","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.6004\/jnccn.2010.0116","volume":"5","author":"GD Demetri","year":"2007","unstructured":"Demetri GD, Benjamin RS, Blanke CD et al (2007) NCCN Task Force report: management of patients with gastrointestinal stromal tumor (GIST)\u2013update of the NCCN clinical practice guidelines. J Natl Compr Canc Netw 5(Suppl 2):S1\u2013S29 (quiz S30)","journal-title":"J Natl Compr Canc Netw"},{"key":"1479_CR5","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1158\/1078-0432.CCR-06-2328","volume":"13","author":"VL Goodman","year":"2007","unstructured":"Goodman VL, Rock EP, Dagher R et al (2007) Approval summary: sunitinib for the treatment of imatinib refractory or intolerant gastrointestinal stromal tumors and advanced renal cell carcinoma. Clin Cancer Res 13:1367\u20131373","journal-title":"Clin Cancer Res"},{"key":"1479_CR6","doi-asserted-by":"crossref","first-page":"4764","DOI":"10.1200\/JCO.2006.06.2265","volume":"24","author":"MC Heinrich","year":"2006","unstructured":"Heinrich MC, Corless CL, Blanke CD et al (2006) Molecular correlates of imatinib resistance in gastrointestinal stromal tumors. J Clin Oncol 24:4764\u20134774","journal-title":"J Clin Oncol"},{"key":"1479_CR7","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1158\/1078-0432.CCR-05-1211","volume":"12","author":"E Wardelmann","year":"2006","unstructured":"Wardelmann E, Merkelbach-Bruse S, Pauls K et al (2006) Polyclonal evolution of multiple secondary KIT mutations in gastrointestinal stromal tumors under treatment with imatinib mesylate. Clin Cancer Res 12:1743\u20131749","journal-title":"Clin Cancer Res"},{"key":"1479_CR8","doi-asserted-by":"crossref","first-page":"717","DOI":"10.2165\/00002018-200932090-00003","volume":"32","author":"N Theou-Anton","year":"2009","unstructured":"Theou-Anton N, Faivre S, Dreyer C, Raymond E (2009) Benefit-risk assessment of sunitinib in gastrointestinal stromal tumours and renal cancer. Drug Saf 32:717\u2013734","journal-title":"Drug Saf"},{"key":"1479_CR9","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/j.bbapap.2009.11.008","volume":"1804","author":"PW Manley","year":"2010","unstructured":"Manley PW, Drueckes P, Fendrich G et al (2010) Extended kinase profile and properties of the protein kinase inhibitor nilotinib. Biochim Biophys Acta 1804:445\u2013453","journal-title":"Biochim Biophys Acta"},{"key":"1479_CR10","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1159\/000091943","volume":"77","author":"H Prenen","year":"2006","unstructured":"Prenen H, Guetens G, de Boeck G et al (2006) Cellular uptake of the tyrosine kinase inhibitors imatinib and AMN107 in gastrointestinal stromal tumor cell lines. Pharmacology 77:11\u201316","journal-title":"Pharmacology"},{"key":"1479_CR11","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1182\/blood-2007-04-083196","volume":"111","author":"P le Coutre","year":"2008","unstructured":"le Coutre P, Ottmann OG, Giles F et al (2008) Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is active in patients with imatinib-resistant or -intolerant accelerated-phase chronic myelogenous leukemia. Blood 111:1834\u20131839","journal-title":"Blood"},{"key":"1479_CR12","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1159\/000198699","volume":"55","author":"A Sevinc","year":"2009","unstructured":"Sevinc A (2009) Activity of nilotinib (AMN-107) alone in advanced gastrointestinal stromal tumors progressing on imatinib and sunitinib. Case report. Chemotherapy 55:132\u2013136","journal-title":"Chemotherapy"},{"key":"1479_CR13","doi-asserted-by":"crossref","first-page":"2293","DOI":"10.1016\/j.ejca.2009.04.030","volume":"45","author":"M Montemurro","year":"2009","unstructured":"Montemurro M, Schoffski P, Reichardt P et al (2009) Nilotinib in the treatment of advanced gastrointestinal stromal tumours resistant to both imatinib and sunitinib. Eur J Cancer 45:2293\u20132297","journal-title":"Eur J Cancer"},{"key":"1479_CR14","doi-asserted-by":"crossref","unstructured":"Tanaka C, Yin OQ, Sethuraman V et al (2010) Clinical pharmacokinetics of the BCR-ABL tyrosine kinase inhibitor nilotinib. Clin Pharmacol Ther 87:197\u2013203","DOI":"10.1038\/clpt.2009.208"},{"key":"1479_CR15","doi-asserted-by":"crossref","unstructured":"Yoo C, Ryu MH, Kang BW et al (2010) Cross-Sectional study of imatinib plasma trough levels in patients with advanced gastrointestinal stromal tumors: impact of gastrointestinal resection on exposure to imatinib. J Clin Oncol 556:43\u201346","DOI":"10.1200\/JCO.2009.26.5785"},{"key":"1479_CR16","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.2214\/ajr.183.6.01831619","volume":"183","author":"H Choi","year":"2004","unstructured":"Choi H, Charnsangavej C, de Castro Faria S et al (2004) CT evaluation of the response of gastrointestinal stromal tumors after imatinib mesylate treatment: a quantitative analysis correlated with FDG PET findings. AJR Am J Roentgenol 183:1619\u20131628","journal-title":"AJR Am J Roentgenol"},{"key":"1479_CR17","doi-asserted-by":"crossref","first-page":"e40","DOI":"10.1259\/bjr\/62872118","volume":"79","author":"KM Linton","year":"2006","unstructured":"Linton KM, Taylor MB, Radford JA (2006) Response evaluation in gastrointestinal stromal tumours treated with imatinib: misdiagnosis of disease progression on CT due to cystic change in liver metastases. Br J Radiol 79:e40\u2013e44","journal-title":"Br J Radiol"},{"key":"1479_CR18","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1093\/jjco\/hyi212","volume":"36","author":"MH Ryu","year":"2006","unstructured":"Ryu MH, Lee JL, Chang HM et al (2006) Patterns of progression in gastrointestinal stromal tumor treated with imatinib mesylate. Jpn J Clin Oncol 36:17\u201324","journal-title":"Jpn J Clin Oncol"},{"key":"1479_CR19","doi-asserted-by":"crossref","first-page":"5910","DOI":"10.1158\/1078-0432.CCR-09-0542","volume":"15","author":"GD Demetri","year":"2009","unstructured":"Demetri GD, Casali PG, Blay JY et al (2009) A phase I study of single-agent nilotinib or in combination with imatinib in patients with imatinib-resistant gastrointestinal stromal tumors. Clin Cancer Res 15:5910\u20135916","journal-title":"Clin Cancer Res"},{"key":"1479_CR20","doi-asserted-by":"crossref","unstructured":"Yin OQ, Gallagher N, Li A et al (2010) Effect of grapefruit juice on the pharmacokinetics of nilotinib in healthy participants. J Clin Pharmacol 50:188\u2013194","DOI":"10.1177\/0091270009336137"},{"issue":"15S","key":"1479_CR21","doi-asserted-by":"crossref","first-page":"7053","DOI":"10.1200\/jco.2009.27.15_suppl.7053","volume":"27","author":"NJ Gallagher","year":"2009","unstructured":"Gallagher NJ, Fischer D, Demirhan E et al (2009) Effect of the proton pump inhibitor esomeprazole on the oral absorption and pharmacokinetics of nilotinib. J Clin Oncol 27(15S):7053","journal-title":"J Clin Oncol"},{"key":"1479_CR22","doi-asserted-by":"crossref","first-page":"4027","DOI":"10.1158\/1078-0432.CCR-07-5015","volume":"14","author":"MW Deininger","year":"2008","unstructured":"Deininger MW (2008) Nilotinib. Clin Cancer Res 14:4027\u20134031","journal-title":"Clin Cancer Res"},{"key":"1479_CR23","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1592\/phco.29.9.1152","volume":"29","author":"C Pavlovsky","year":"2009","unstructured":"Pavlovsky C, Egorin MJ, Shah DD et al (2009) Imatinib mesylate pharmacokinetics before and after sleeve gastrectomy in a morbidly obese patient with chronic myeloid leukemia. Pharmacotherapy 29:1152\u20131156","journal-title":"Pharmacotherapy"},{"key":"1479_CR24","doi-asserted-by":"crossref","first-page":"3141","DOI":"10.1200\/JCO.2008.20.4818","volume":"27","author":"GD Demetri","year":"2009","unstructured":"Demetri GD, Wang Y, Wehrle E et al (2009) Imatinib plasma levels are correlated with clinical benefit in patients with unresectable\/metastatic gastrointestinal stromal tumors. J Clin Oncol 27:3141\u20133147","journal-title":"J Clin Oncol"},{"key":"1479_CR25","doi-asserted-by":"crossref","first-page":"3496","DOI":"10.1182\/blood-2006-07-036012","volume":"109","author":"S Picard","year":"2007","unstructured":"Picard S, Titier K, Etienne G et al (2007) Trough imatinib plasma levels are associated with both cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia. Blood 109:3496\u20133499","journal-title":"Blood"},{"key":"1479_CR26","doi-asserted-by":"crossref","first-page":"1982","DOI":"10.1016\/j.jchromb.2009.04.045","volume":"877","author":"A Haouala","year":"2009","unstructured":"Haouala A, Zanolari B, Rochat B et al (2009) Therapeutic drug monitoring of the new targeted anticancer agents imatinib, nilotinib, dasatinib, sunitinib, sorafenib and lapatinib by LC tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 877:1982\u20131996","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-010-1479-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00280-010-1479-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-010-1479-6","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,12]],"date-time":"2021-11-12T01:38:19Z","timestamp":1636681099000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00280-010-1479-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,10,19]]},"references-count":26,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2011,8]]}},"alternative-id":["1479"],"URL":"https:\/\/doi.org\/10.1007\/s00280-010-1479-6","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"value":"0344-5704","type":"print"},{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,10,19]]}}}